Open AccessComparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
Author(s) -
Kevin Zarrabi,
Elizabeth A. Handorf,
Benjamin Miron,
Matthew R. Zibelman,
Fern Anari,
Pooja Ghatalia,
Elizabeth R. Plimack,
Daniel M. Geynisman
Publication year - 2022
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1093/oncolo/oyac195
Subject(s) - medicine , ipilimumab , axitinib , nivolumab , pembrolizumab , renal cell carcinoma , oncology , proportional hazards model , population , immunotherapy , cancer , sunitinib , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom